FreshChems is pleased to introduce dpDMC (N-Dipropyl-Dimethocaine), an orally active dopamine reuptake inhibitor (DRI) and a structural analog of DMC. Unlike DMC, which at higher doses can cause sedation due to sodium channel blockade, dpDMC has been designed to retain its dopaminergic profile while markedly reducing this side effect. Even after repeated high-dose administration, no signs of sedation or excessive motor stimulation are observed, unlike with DMC.
Routes and administration parameters in large mammals:
Oral route: stimulant effects in animals have been observed in the 100–250 mg range per large mammal of average body mass.
Mucous absorption: minimal to negligible; oral administration is required for activity.
Average duration of effect: up to 3 hours.
Observations: response may vary between specimens. Most exhibit a pronounced and sustained dopaminergic activation (stimulant), while others show only mild tone elevation or no detectable behavioral response.
Notice:
The information provided herein is derived from scientific sources and is supplied solely to indicate the relevant field of research and study.
Any use of the referenced substances or information on living beings is strictly prohibited unless expressly authorized by the competent authorities and carried out within the scope of an appropriate professional qualification, in full compliance with applicable laws and regulations.